Get the Stockscreener App
11.11
1.09%
0.12
After Hours:
11.11
Zevra Therapeutics Inc stock is traded at $11.11, with a volume of 863.17K.
It is up +1.09% in the last 24 hours and up +26.11% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$10.99
Open:
$10.97
24h Volume:
863.17K
Relative Volume:
1.02
Market Cap:
$607.49M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-8.6124
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-4.80%
1M Performance:
+26.11%
6M Performance:
+41.71%
1Y Performance:
+71.19%
1-Day Range:
$10.84
$11.33
1-Week Range:
$10.69
$11.71
52-Week Range:
$6.10
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
11.11 | 600.93M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect? - Yahoo Finance
Applying Elliott Wave Theory to Zevra Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it
How Zevra Therapeutics Inc. stock performs during market volatilitySecure Capital Picks With Upside Potential Tracked - metal.it
Despite currently being unprofitable, Zevra Therapeutics (NASDAQ:ZVRA) has delivered a 102% return to shareholders over 3 years - simplywall.st
What institutional investors are buying Zevra Therapeutics Inc. stockMarket Forecast Alerts For Smart Trading - jammulinksnews.com
How strong is Zevra Therapeutics Inc. company’s balance sheetDaily Trading Review That Work - jammulinksnews.com
What catalysts could drive Zevra Therapeutics Inc. stock higher in 2025Expert Picks Data Feed For Consistent Profits - jammulinksnews.com
Zevra Therapeutics' Strategic Expansion into the European Market with Arimoclomol for NPC: A Deep Dive into Regulatory, Commercial, and Market Access Potential - AInvest
How many analysts rate Zevra Therapeutics Inc. as a “Buy”Consistent triple returns - jammulinksnews.com
Zevra Therapeutics Submits Marketing Authorization Application t - GuruFocus
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C | ZVRA Stock News - GuruFocus
ZVRA: Zevra Therapeutics Seeks EMA Approval for NPC Drug Arimoclomol - GuruFocus
Should I hold or sell Zevra Therapeutics Inc. stock in 2025Market Forecast Target Finder For Every Investor - jammulinksnews.com
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C - GlobeNewswire
Zevra's Breakthrough NPC Treatment Heads to EMA Review: 270+ Patient Data Shows Promise - Stock Titan
Is Zevra Therapeutics Inc. a growth stock or a value stockSuperior profit margins - jammulinksnews.com
Intrinsic Value of Zevra Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree High-Accuracy Stock Picks - metal.it
What are analysts’ price targets for Zevra Therapeutics Inc. in the next 12 monthsGame-changing capital returns - jammulinksnews.com
Published on: 2025-07-28 03:53:57 - jammulinksnews.com
Is Zevra Therapeutics Inc. stock overhyped or has real potentialMarket Timing Advice - metal.it
What makes Zevra Therapeutics Inc. stock price move sharplyFree Deep Market Trend Analysis - metal.it
What drives Zevra Therapeutics Inc. stock priceSky-high profits - PrintWeekIndia
What analysts say about Zevra Therapeutics Inc. stockSuperior stock growth - PrintWeekIndia
Zevra Therapeutics Inc. Stock Analysis and ForecastExplosive wealth accumulation - jammulinksnews.com
Is Zevra Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire
Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases - TipRanks
ZVRA Showcases Key Findings on MIPLYFFA and OLPRUVA at Genetics - GuruFocus
Zevra Therapeutics Highlights Research on MIPLYFFA® and OLPRUVA® at 42nd Annual SERGG Meeting - Nasdaq
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):